HilleVax (HLVX) announced the appointment of Ozzie Berger as Senior Vice President of Regulatory Affairs, the promotion of Anju Chatterji to Chief Technical Officer, and the promotion of Shane Maltbie to Chief Financial Officer. As part of a planned transition in connection with Maltbie’s promotion, David Socks will focus on business development activities as the company’s Chief Business Officer. Berger brings to HilleVax nearly three decades of expertise in creating and implementing innovative regulatory strategies across all phases of product development and commercialization. Prior to joining HilleVax, Berger was Vice President and Global Regulatory Head for GSK‘s (GSK) Vaccine Therapeutic Group. Dr. Chatterji has more than 20 years of experience implementing CMC development and manufacturing strategies to drive successful global regulatory filings and approvals. She served as Senior Vice President of Technical Operations for HilleVax since joining the company in January 2022. Maltbie was previously Vice President of Finance at HilleVax and has two decades of experience in finance operations, including building and leading multiple finance organizations.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HLVX:
- HilleVax Announces Executive Management Appointments and Promotions
- HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
- HilleVax reports results from ongoing Phase 2b trial of HIL-214
- HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
- HilleVax to Participate in November Investor Conferences